- Report
- August 2025
- 184 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 188 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 181 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 184 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 198 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- July 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- April 2025
- 183 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- March 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- February 2025
- 186 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- January 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- January 2025
- 185 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- October 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- December 2025
- 396 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 467 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 392 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 384 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 192 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 485 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 274 Pages
Global
From €5160EUR$5,850USD£4,533GBP

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated.
Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss.
In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR.
The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR.
Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more